ustekinumab-aekn
ustekinumab-aekn is listed in the FDA National Drug Code directory with 12 NDC codes, marketed under brand names including Ustekinumab-aekn, Selarsdi, SELARSDI. Available dosage form: injection, solution.
Drug Details
- Generic Name
- ustekinumab-aekn
- Brand Names
- Ustekinumab-aekn, Selarsdi, SELARSDI
- Application Number
- BLA761343
- Sponsor
- Teva Pharmaceuticals USA, Inc.
- NDC Codes
- 12
- Dosage Forms
- INJECTION, SOLUTION
- Routes
- SUBCUTANEOUS, INTRAVENOUS
- Active Ingredients
- USTEKINUMAB-AEKN, USTEKINUMAB
Indications and Usage
1 INDICATIONS AND USAGE SELARSDI is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 ) moderately to severely active Crohn’s disease (CD). ( 1.3 ) moderately to severely active ulcerative colitis. ( 1.4 ) Pediatric patients 6 years and older with: moderate to severe plaque psoriasis, who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 ) 1.1 Plaque Psoriasis (PsO) SELARSDI™ is indicated for the treatment of adults and pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. 1.2 Psoriatic Arthritis (PsA) SELARSDI is indicated for the treatment of adults and pediatric patients 6 years of age and older with active psoriatic arthritis. 1.3 Crohn’s Disease (CD) SELARSDI is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease. 1.4 Ulcerative Colitis SELARSDI is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.